Does the media refer more to LIVN or PRCT?

In the previous week, LivaNova and LivaNova both had 3 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.72 beat LivaNova's score of 0.93 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, MMED or PRCT?

MiniMed Group has higher revenue and earnings than PROCEPT BioRobotics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.34 N/A N/A N/A PROCEPT BioRobotics $322.02M 3.99 -$95.57M -$1.82 N/A

Does the media refer more to MMED or PRCT?

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than MiniMed Group. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for MiniMed Group. PROCEPT BioRobotics' average media sentiment score of 1.72 beat MiniMed Group's score of 0.96 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PRCT or IRTC?

In the previous week, PROCEPT BioRobotics and PROCEPT BioRobotics both had 3 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.72 beat iRhythm Technologies' score of 0.92 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive iRhythm Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor WRBY or PRCT?

In the previous week, Warby Parker had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 7 mentions for Warby Parker and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 1.72 beat Warby Parker's score of 0.62 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

PROCEPT BioRobotics (PRCT) Competitors

$22.56 +1.07 (+4.98%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$22.28 -0.29 (-1.26%)

As of 06/26/2026 07:18 PM Eastern

Compare

PRCT vs. LIVN, NVST, MMED, IRTC, and WRBY

Should you buy PROCEPT BioRobotics stock or one of its competitors? MarketBeat compares PROCEPT BioRobotics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PROCEPT BioRobotics include LivaNova (LIVN), Envista (NVST), MiniMed Group (MMED), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does PROCEPT BioRobotics compare to LivaNova?

LivaNova (NASDAQ:LIVN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

LivaNova has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

LivaNova has a net margin of 7.48% compared to PROCEPT BioRobotics' net margin of -31.82%. LivaNova's return on equity of 16.48% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

PROCEPT BioRobotics has lower revenue, but higher earnings than LivaNova. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.30	-$242.47M	$1.95	42.76
PROCEPT BioRobotics	$322.02M	3.99	-$95.57M	-$1.82	N/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LivaNova currently has a consensus target price of $80.75, indicating a potential downside of 3.16%. PROCEPT BioRobotics has a consensus target price of $40.42, indicating a potential upside of 79.15%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

In the previous week, LivaNova and LivaNova both had 3 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.72 beat LivaNova's score of 0.93 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

LivaNova beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Envista?

Envista (NYSE:NVST) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.0% of Envista shares are held by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Envista. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 0 mentions for Envista. PROCEPT BioRobotics' average media sentiment score of 1.72 beat Envista's score of 0.83 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Overall Sentiment
Envista	Positive
PROCEPT BioRobotics	Very Positive

Envista currently has a consensus target price of $28.67, indicating a potential upside of 6.29%. PROCEPT BioRobotics has a consensus target price of $40.42, indicating a potential upside of 79.15%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

Envista has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Envista has a net margin of 2.41% compared to PROCEPT BioRobotics' net margin of -31.82%. Envista's return on equity of 7.11% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Envista has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.61	$47M	$0.41	65.78
PROCEPT BioRobotics	$322.02M	3.99	-$95.57M	-$1.82	N/A

Summary

PROCEPT BioRobotics beats Envista on 9 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

MiniMed Group has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -31.82%. MiniMed Group's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

19.7% of MiniMed Group shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MiniMed Group has higher revenue and earnings than PROCEPT BioRobotics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.34	N/A	N/A	N/A
PROCEPT BioRobotics	$322.02M	3.99	-$95.57M	-$1.82	N/A

MiniMed Group currently has a consensus price target of $21.33, suggesting a potential upside of 49.81%. PROCEPT BioRobotics has a consensus price target of $40.42, suggesting a potential upside of 79.15%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than MiniMed Group. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for MiniMed Group. PROCEPT BioRobotics' average media sentiment score of 1.72 beat MiniMed Group's score of 0.96 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

PROCEPT BioRobotics beats MiniMed Group on 7 of the 13 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to iRhythm Technologies?

PROCEPT BioRobotics (NASDAQ:PRCT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

iRhythm Technologies has a net margin of -3.53% compared to PROCEPT BioRobotics' net margin of -31.82%. iRhythm Technologies' return on equity of -10.26% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

PROCEPT BioRobotics currently has a consensus price target of $40.42, indicating a potential upside of 79.15%. iRhythm Technologies has a consensus price target of $187.38, indicating a potential upside of 57.61%. Given PROCEPT BioRobotics' higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

PROCEPT BioRobotics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

iRhythm Technologies has higher revenue and earnings than PROCEPT BioRobotics. iRhythm Technologies is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$322.02M	3.99	-$95.57M	-$1.82	N/A
iRhythm Technologies	$747.14M	5.23	-$44.55M	-$0.86	N/A

In the previous week, PROCEPT BioRobotics and PROCEPT BioRobotics both had 3 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.72 beat iRhythm Technologies' score of 0.92 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
iRhythm Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRhythm Technologies beats PROCEPT BioRobotics on 11 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Warby Parker?

Warby Parker (NYSE:WRBY) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Warby Parker has a net margin of 0.15% compared to PROCEPT BioRobotics' net margin of -31.82%. Warby Parker's return on equity of 2.30% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Warby Parker currently has a consensus price target of $29.50, indicating a potential upside of 1.34%. PROCEPT BioRobotics has a consensus price target of $40.42, indicating a potential upside of 79.15%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

In the previous week, Warby Parker had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 7 mentions for Warby Parker and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 1.72 beat Warby Parker's score of 0.62 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

93.2% of Warby Parker shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 16.8% of Warby Parker shares are held by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Warby Parker has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$890.57M	3.50	$1.64M	$0.02	1,455.50
PROCEPT BioRobotics	$322.02M	3.99	-$95.57M	-$1.82	N/A

Warby Parker has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Summary

Warby Parker beats PROCEPT BioRobotics on 13 of the 17 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRCT vs. The Competition

Export

Metric	PROCEPT BioRobotics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$7.37B	$6.70B	$12.22B
Dividend Yield	N/A	1.26%	2.67%	6.13%
P/E Ratio	-12.40	51.24	25.84	24.18
Price / Sales	3.99	93.05	576.85	114.69
Price / Cash	N/A	25.94	46.99	54.37
Price / Book	3.44	7.56	10.78	6.36
Net Income	-$95.57M	$159.20M	$3.58B	$337.99M
7 Day Performance	3.87%	1.80%	2.22%	0.10%
1 Month Performance	-14.74%	0.05%	1.11%	-0.11%
1 Year Performance	-60.36%	5.96%	34.28%	27.60%

PROCEPT BioRobotics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRCT PROCEPT BioRobotics	3.245 of 5 stars	$22.56 +5.0%	$40.42 +79.2%	-61.5%	$1.28B	$322.02M	N/A	430	Analyst Upgrade
LIVN LivaNova	1.5821 of 5 stars	$78.71 +0.3%	$80.75 +2.6%	+82.1%	$4.31B	$1.39B	40.36	3,300
NVST Envista	1.5063 of 5 stars	$25.50 -1.6%	$28.67 +12.4%	+37.1%	$4.22B	$2.72B	62.20	12,000
MMED MiniMed Group	3.8425 of 5 stars	$14.22 -3.7%	$21.33 +50.0%	N/A	$3.99B	$2.99B	N/A	8,000
IRTC iRhythm Technologies	4.5154 of 5 stars	$104.69 +0.0%	$187.38 +79.0%	-22.1%	$3.44B	$787.85M	N/A	2,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRCT) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. LIVN, NVST, MMED, IRTC, and WRBY

How does PROCEPT BioRobotics compare to LivaNova?

Summary

How does PROCEPT BioRobotics compare to Envista?

Summary

How does PROCEPT BioRobotics compare to MiniMed Group?

Summary

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Summary

How does PROCEPT BioRobotics compare to Warby Parker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. LIVN, NVST, MMED, IRTC, and WRBY

How does PROCEPT BioRobotics compare to LivaNova?

Which has more risk and volatility, LIVN or PRCT?

Is LIVN or PRCT more profitable?

Which has higher valuation and earnings, LIVN or PRCT?

Do institutionals and insiders believe in LIVN or PRCT?

Do analysts rate LIVN or PRCT?

Does the media refer more to LIVN or PRCT?

Summary

How does PROCEPT BioRobotics compare to Envista?

Do institutionals & insiders hold more shares of NVST or PRCT?

Does the media favor NVST or PRCT?

Do analysts rate NVST or PRCT?

Which has more volatility and risk, NVST or PRCT?

Is NVST or PRCT more profitable?

Which has preferable earnings and valuation, NVST or PRCT?

Summary

How does PROCEPT BioRobotics compare to MiniMed Group?

Is MMED or PRCT more profitable?

Do institutionals and insiders have more ownership in MMED or PRCT?

Which has better valuation & earnings, MMED or PRCT?

Do analysts recommend MMED or PRCT?

Does the media refer more to MMED or PRCT?

Summary

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Do institutionals & insiders believe in PRCT or IRTC?

Is PRCT or IRTC more profitable?

Do analysts recommend PRCT or IRTC?

Which has more risk and volatility, PRCT or IRTC?

Which has stronger earnings and valuation, PRCT or IRTC?

Does the media prefer PRCT or IRTC?

Summary

How does PROCEPT BioRobotics compare to Warby Parker?

Is WRBY or PRCT more profitable?

Do analysts rate WRBY or PRCT?

Does the media favor WRBY or PRCT?

Do institutionals and insiders believe in WRBY or PRCT?

Which has stronger earnings & valuation, WRBY or PRCT?

Which has more risk and volatility, WRBY or PRCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools